Journals / İnönü Üniversitesi Tıp Fakültesi Dergisi / 2011 / Cilt: 18 - Sayı: 2

Efficiency of tigecycline and other antimicrobials to extended spectrum beta lactamase producing gram negative bacteria in blood culture ısolates and detection in activity of carbapenemases

Kan kültürlerinden izole edilen genişlemiş spektrumlu beta laktamaz üreten gram negatif bakterilerde tigesiklin ve diğer antimikrobiyallerin in vitro etkinliği ve karbapenemaz aktivitesinin araştırılması

Pages
106–110
Publication Date
2022-10-17
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

In result of ESBL-producing gram-negative bacteria in blood cultures, all isolates were found to be susceptible to amikacin, meropenem, tigecycline, and carbapenemase activity was not determined.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:The extended spectrum beta lactamase (ESBL) producing Esherichia coli and Klebsiella spp. has become a worlwide problem.
📊
Key Findings & Data:Tigecycline (the GAR-936) is a new glycylcycline antibiotic has shown in vitro activity against many multidrug-resistant pathogen.
💡
Conclusion & Impact:In result of ESBL-producing gram-negative bacteria in blood cultures, all isolates were found to be susceptible to amikacin, meropenem, tigecycline, and carbapenemase activity was not determined.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

The extended spectrum beta lactamase (ESBL) producing Esherichia coli and Klebsiella spp. has become a worlwide problem. Tigecycline (the GAR-936) is a new glycylcycline antibiotic has shown in vitro activity against many multidrug-resistant pathogen. In this study, efficiency of tigecycline, amoxicillin/clavulanate, ceftazidime, ceftriaxone, cefepime, piperacillin/tazobactam, levofloxacin, minocycline, ampicillin, amikacin, meropenem were investigated using broth microdilution method in 49 (42 Esherichia coli, 7 Klebsiella spp.) ESBL-producing gram negative bacteria in bloodstream infection isolates. Antimicrobial activity were low for except amikacin, meropenem and tigecycline. MIC 50 and MIC90 values for tigecycline were determined as 0.5 μg/ml and 0.5 μg/ml and MIC range; 0.12- 1μg/ml for Esherichia coli strains, MIC range 0.5- 1 μg/ml for Klebsiella strains. Ertapenem disk-diffusion method and Modified Hodge test (MHT) were used for carbapenemase activity. In forty seven isolates were not detected for carbapenemase activity with MHT. Carbapenemase activity for two isolates could not be evaluated because of inhibitory activity. In result of ESBL-producing gram-negative bacteria in blood cultures, all isolates were found to be susceptible to amikacin, meropenem, tigecycline, and carbapenemase activity was not determined.

Özet

Genişlemiş Spektrumlu Beta Laktamaz (GSBL) üreten Esherichia coli ve Klebsiella izolatları tüm dünyada önemli bir problemdir. Yeni bir glisilsiklin antibiyotik olan tigesiklin (GAR-936) çoğul ilaç direnci olan birçok patojene karşı invitro etkili görünmektedir. Bu çalışmada kan kültürlerinden izole edilen, GSBL üreten 49 (42 Esherichia coli, 7 Klebsiella spp.) izolatta tigesiklin, amoksisilin/klavulanik asit, seftazidim, seftriakson, sefepim, piperasilin/tazobaktam, levofloksasilin, minosiklin, ampisilin, amikasin, meropenem etkinliği buyyon mikrodilüsyon yöntemi ile belirlendi. Amikasin, meropenem ve tigesiklin dışındaki antimikrobiyallerin etkinliği oldukça düşük bulundu. Tigesiklinin MİK50 ve MİK90 değerleri sırası ile Esherichia coli için 0.5 μg/ml, 0.5 μg/ml ve MİK aralığı 0.12-1 μg/ml; Klebsiella suşlarında ise tigesiklin MİK aralığı 0.5-1 μg/ml olarak tespit edildi. Ertapenem disk difüzyon yöntemi ve Modifiye Hodge testi (MHT) karbapenemaz aktivitesi için kullanıldı. MHT ile kırk yedi izolatta karbapenemaz aktivitesi saptanmadı. İki izolatta ise karbapenemaz aktivitesi inhibisyon alanı oluşturduğu için değerlendirilemedi. Sonuç olarak hastanemizde kan kültürlerinden izole edilen GSBL üreten izolatların hepsi amikasin, meropenem ve tigesikline duyarlı bulunmuş, karbapenemaz aktivitesi saptanmamıştır.

🔖

Cite This Article

KUZUCU, Ç., TETKİN, F., ERSOY, Y., GÖRGEÇ, S. (2022). Efficiency of tigecycline and other antimicrobials to extended spectrum beta lactamase producing gram negative bacteria in blood culture ısolates and detection in activity of carbapenemases. İnönü Üniversitesi Tıp Fakültesi Dergisi, Cilt: 18 - Sayı: 2, 106–110. https://ajindex.com/articles/548463

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (15)

  1. Canto´n R, Novais A, Valverde A, et al. Prevalence and spread of extended-spectrum β-lactamase-producing Enterobacteriaceae in Europe. Clin Microbiol Infect 2008; 14 (Suppl. 1): 144-53
  2. Villegas MV, Kattan JN, Quinteros MG, et al. Prevalence of extended-spectrum β-lactamases in South America. Clin Microbiol Infect 2008; 14 (Suppl. 1):154-8
  3. Paterson DL, Bonomo RA. Extended-Spectrum β-Lactamases: A clinical update. Clin Microbiol Rev 2005;18: 657–86
  4. Poirel L, Heritier C, Spicq C, Nordmann P. In vivo acquisition of high-level resistance to imipenem in Escherichia coli. J Clın Mıcrobıol 2004; 42: 3831-3
  5. Akalın H. Kolistin. ANKEM Derg 2007; 21(Ek 2): 26-8
  6. Petersen PJ, Jacobus NV, Weıss WJ, Sum PE, Testa RT. In vitro and in vivo antibacterial activities of a novel glycylcycline, the 9-t-butylglycylamido derivative of minocycline (GAR-936). antimicrob Agents Chemother 1999; 43: 73-44
  7. Wyeth Pharmaceuticals Inc.: Tygacil Product Insert, June 2005, Philadelphia (PA),
  8. Clinical and Laboratory Standards Institute: Performance standards for antimicrobial susceptibility testing; Nineteenth informational supplement. CLSI document M 100- S19, Clinical and Laboratory Standards Institute 2009; Wayne, Pennsylvania
  9. Schwaber MJ, Carmeli Y. Mortality and delay in effective therapy associated with extended-spectrum β-lactamase production in Enterobacteriaceae bacteraemia: a systematic review and meta-analysis. J Antimicrob Chemother 2007; 60: 913-20
  10. Bagattini M, Crivaro V, Popola AD, Gentile F, Scarcella A, Triassi M, Villari P, Zarrilli R. Molecular epidemiology of extended-spectrum β-lactamase-producing Klebsiella pneumoniae in a neonatal intensive care unit. J Antimicrob Chemother 2006; 57:979-82
  11. Giske CG, Monnet DL, Cars O, et al. Clinical and economic impact of common multidrug-resistant gram-negative bacilli. Antimicrob Agents Chemother 2008;52:813-21
  12. Yetkin G, Kuzucu Ç, Çalışkan A, Ay S. Kan kültürlerinde üreyen Esherichia coli’lerin antibiyotik duyarlılıkları, GSBL oranları ve hastane birimlerine göre dağılımı. İnönü Üniv. Tıp Fak. Dergisi 2006;13:147-50
  13. Poirel L,Villa L, Bertini A et al. Expanded-spectrum β-lactamase and plasmid-mediated quinolone resistance. Emerg Infect Dis 2007; 13: 803-4
  14. Moolman GJJ, Jankowitz CE, Bezuidenhout S, Pitout DD. Beta-lactamases in Enterobacteriaceae an ever present threat. SAMJ 2006; 96: 331-4
  15. Chaibi EB, Sirot D, Paul G et al. Inhibitor-resistant TEM ßl